Latest Breaking News On - Tariq arshad - Page 3 : vimarsana.com

Qualigen Therapeutics Presents Data On QN-247 in Triple

In Vivo Efficacy Study Demonstrates QN-247 as Potential Therapeutic Approach in Rare Breast Cancer Type CARLSBAD, Calif., April 18, 2023 (GLOBE.

United statesAndrew hertigJules abrahamTariq arshadMichael poirierMarkj sarnoAmerican association for cancer researchAboutqualigentherapeutics incPartners incQualigen therapeutics incVivo efficacy study demonstratesPotential therapeutic approachRare breast cancerOrphan drug designationAmerican associationCancer research

Data on Potential Biomarker for Qualigen Therapeutics Lead Program QN-302 Published in Peer-Reviewed Journal Molecules

Data on Potential Biomarker for Qualigen Therapeutics Lead Program QN-302 Published in Peer-Reviewed Journal Molecules
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesTariq arshadExchange commissionJules abrahamjqa partners incQualigen therapeutics incAboutqualigentherapeutics incWall streetGene expression may be markerAnti tumor activityOrphan drug designationChief medical officerQualigen therapeuticsFast trackOrphan drugPrivate securities litigation reform act

Qualigen Therapeutics (QLGN) Announces Pre-IND Feedback from U S Food and Drug Administration Regarding QN-302 for the Treatment of G4-Targeted Advanced Solid Tumors

Qualigen Therapeutics (QLGN) Announces Pre-IND Feedback from U S Food and Drug Administration Regarding QN-302 for the Treatment of G4-Targeted Advanced Solid Tumors
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Tariq arshadMichael poirierQualigen therapeutics incOrphan drug designationInvestigational new drugChief medicalScientific advisory board

Qualigen Therapeutics Announces Pre-IND Feedback from U S Food and Drug Administration Regarding QN-302 for the Treatment of G4-Targeted Advanced Solid Tumors

Qualigen Therapeutics Announces Pre-IND Feedback from U S Food and Drug Administration Regarding QN-302 for the Treatment of G4-Targeted Advanced Solid Tumors
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Tariq arshadMichael poirierExchange commissionJules abrahamjqa partners incQualigen therapeutics incAboutqualigentherapeutics incOrphan drug designationInvestigational new drugChief medicalScientific advisory boardQualigen therapeuticsFast trackOrphan drugPrivate securities litigation reform act

Qualigen Therapeutics Presents Data on QN-302 at AACR s

Posters include data regarding 1) mode of action, and 2) preclinical toxicology CARLSBAD, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) Qualigen.

United statesStephen neidleJules abrahamTariq arshadExchange commissionPartners incAmerican academy of cancer researchQualigen therapeutics incAboutqualigentherapeutics incOrphan drug designationAmerican academyCancer researchSpecial conferencePancreatic cancerChief medicalInvestigational new drug